Marcello Aragona
University of Messina
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Marcello Aragona.
Tumori | 2001
R. Maisano; Nicola Caristi; Giuseppe Toscano; Marcello Aragona; Pietro Spadaro; Placido Amadio; Marzia Mare; Maria Zavettieri; Francesco La Torre
Aims and Background The treatment of inoperable malignant pleural mesothelioma is a challenge for the oncologist. Available chemotherapy regimens achieve poor results, therefore new agents or combinations are needed. In a phase I study, the combination of oxaliplatin and raltitrexed was shown to be active against malignant pleural mesothelioma. We herein report the results of a pilot study about the treatment of this disease. Methods From April 1999 to June 2000, we enrolled 11 chemotherapy-naïve patients with inoperable malignant pleural mesothelioma suitable to receive the following combination chemotherapy: raltitrexed, 3 mg/m2 iv, and oxaliplatin, 130 mg/m2, as a 2-hr infusion every 3 weeks. Results Four partial responses, 1 regression of disease (objective response rate, 45%; 95% Cl, 15.6-74.4%), 4 stable diseases and 2 progressions of disease were observed. An improvement in disease-related symptoms was recorded in all responders and in 2 patients with stable disease. Toxicity was mild, with no toxic-related death and only 1 episode of grade 4 neurotoxicity. Conclusions We consider the combination promising and worthy of further studies.
Cancer Investigation | 2001
Marcello Aragona; Stefania Panetta; Anna Maria Silipigni; Domenico Leo Romeo; Giuseppe Pastura; Mario Mesiti; Stefano Cascinu; Francesco La Torre
Nerve growth factor receptor (NGF-R) has been shown to have antiproliferative, differentiative, or apoptotic effects on some types of tumor cells, whereas in others it may have mitogenic activity. The immunohistochemical distribution of NGF-R was analyzed in a series of tissue samples from breast cancer patients and its relationship with other clinical and pathological parameters was studied. The distribution of NGF-R was evaluated by immunohistochemistry in frozen tissue samples of 46 breast cancer patients (ME20-4 monoclonal anti-NGF-R). NGF-R immunoreactivity was localized in the plasma membrane of myoepithelial cells, differentiated ducts, neoplastic cells, blood vessels, and nerve fibers in 26 patients (57%). Less differentiated neoplastic tissues were usually NGF-R negative. NGF-R immunoreactivity was associated with estrogen receptor (ER) status (p = 0.02), small tumor dimension (pT) (p = 0.04), low histologic grade (G1–G2) (p < 0.05), old age(p = 0.02), menopause (p = 0.02), and long disease-free survival (DFS) (median follow up 86 months; p = 0.03; independently from ER, pT, age, menopause by multivariate analysis, p = 0.0078). The expression of NGF-R immunoreactivity by breast cancer patients with long DFS may represent a crucial step both in the differentiation status of neoplasia and in the host immune mechanism controlling tumor growth and metastasization.
Psychological Reports | 2006
Maria Rosaria Anna Muscatello; Antonio Bruno; C. Carroccio; Clemente Cedro; D. La Torre; A. E. Di Rosa; Rocco Zoccali; Marcello Aragona; F La Torre; Antonella Mattei; Anna Maria Angelone; F. Di Orio
The prevalence of burnout in oncology staff was compared with that of the ophthalmology staff, who normally present a low prevalence of burnout as described in this literature. The correlation of burnout with the emotion of anger was also investigated. Thirty-six subjects working in an oncology department and 32 working in an ophthalmology department were examined using the Maslach Burnout Inventory and the State-Trait Anger Expression Inventory. The oncology group showed higher mean scores on the MBI Emotive Exhaustion and Depersonalization scales with respect to ophthalmology staff. Correlation analysis showed that increasing burnout was associated with higher anger expressed towards the environment and loss of anger control. Anger, as a response to frustration, appears to be a feature constantly associated with the clinical expression of burnout and it should not be underestimated in theoretical and preventive contexts.
Annals of the New York Academy of Sciences | 2006
M. T. Fera; M. Carbone; C. Buda; Marcello Aragona; Stefania Panetta; M. Giannone; F. Torre; A. Giudice; E. Losi
Abstract: Our data indicate that H. pylori infection is associated with active interleukin‐18 production in patients with chronic gastritis. Different cell types appear to be involved in this activity and may play a role in the development of immunopathologic damage.
General Pharmacology-the Vascular System | 1996
Giovambattista De Sarro; Maria Carla Liberto; Maria Concetta Berlinghieri; Alfredo Focà; Marcello Aragona; Riccardo Cavaliere; Elio Gulletta
1. In genetically epilepsy-prone rats (GEPR-9s), which represent a natural genetic model of epilepsy, we observed that the number of peritoneal macrophages was significantly lower with respect to normal rats, and that some functional parameters (i.e. phagocytosis and intracellular killing) of these macrophages were impaired. 2. The count of lymphocyte populations showed a predominance of T-helper over T-cytotoxic/suppressor both in the spleen and lymph nodes. Moreover, an increased T-cell/B-cell ratio was observed in GEPR-9s. Flow cytometry revealed that GEPR-9s spleens possessed a large percentage of T-helper cells in comparison to normal rats. 3. By using concanavalin A-induced proliferation of GEPR-9s cultured lymphocytes, we have shown increased functional activation. 4. We suggest that the alterations in T-cell functions in GEPR-9s could be due to the involvement of the neuroendocrine system in the modulation of immunity, in the shift between Th1 and Th2, and in the activation of stress response.
International Journal of Oncology | 2000
Marcello Aragona; R. Maisano; Stefania Panetta; A Giudice; Maria Morelli; I. La Torre; F La Torre
Journal of Experimental & Clinical Cancer Research | 1997
Marcello Aragona; Maria Rosaria Anna Muscatello; Mesiti M
Minerva Medica | 1997
La Torre F; Orlando A; Silipigni Am; Giacobello T; Pergolizzi S; Marcello Aragona
Oncology Reports | 2000
Marcello Aragona; C. A. Buda; Stefania Panetta; Maria Morelli; A Giudice; F. L. Campagna; A. Pontoriero; S Cascinu; F La Torre
Annals of the New York Academy of Sciences | 1996
Marcello Aragona; Maria Rosaria Anna Muscatello; Mesiti M